Last reviewed · How we verify

ASST Gaetano Pini-CTO — Portfolio Competitive Intelligence Brief

ASST Gaetano Pini-CTO pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Levobupivacaine 0,125% Levobupivacaine 0,125% marketed
Mepivacaine 1% Mepivacaine 1% marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia
Levobupivacaine 0,5% Levobupivacaine 0,5% marketed Local anesthetic (amide) Voltage-gated sodium channels Anesthesia

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Tiantan Hospital · 1 shared drug class
  2. Bozyaka Training and Research Hospital · 1 shared drug class
  3. Centre Hospitalier Departemental Vendee · 1 shared drug class
  4. Centre Hospitalier Universitaire de Nīmes · 1 shared drug class
  5. Chiang Mai University · 1 shared drug class
  6. China Medical University, China · 1 shared drug class
  7. Ciusss de L'Est de l'Île de Montréal · 1 shared drug class
  8. Assistance Publique - Hôpitaux de Paris · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ASST Gaetano Pini-CTO:

Cite this brief

Drug Landscape (2026). ASST Gaetano Pini-CTO — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/asst-gaetano-pini-cto. Accessed 2026-05-16.

Related